Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
05/2010
05/27/2010US20100130598 Methods for inducing programmed cell death
05/27/2010US20100130597 Dna-pkcs modulates energy regulation and brain function
05/27/2010US20100130596 Rad51 derived cancer cell specific promoters for targeted anti- cancer therapy
05/27/2010US20100130595 Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
05/27/2010US20100130594 Cns gene delivery using peripheral administration of aav vectors
05/27/2010US20100130593 autoimmune or inflammatory diseases; multiple sclerosis, diabetes mellitus
05/27/2010US20100130592 RNA Interference Mediated Inhibition of GRB2 Associated Binding Protein (GAB2) Gene Expression Using Short Interfering Nucleic Acid (siNA)
05/27/2010US20100130591 Multiple exon skipping compositions for dmd
05/27/2010US20100130590 Deletion bearing bard1 isoforms and use thereof
05/27/2010US20100130589 MODULATION OF eIF4E EXPRESSION
05/27/2010US20100130588 Novel lipid formulations for nucleic acid delivery
05/27/2010US20100130587 METHODS OF TREATING CANCER USING siRNA MOLECULES DIRECTED AGAINST CD24
05/27/2010US20100130586 Diagnosis and treatment of t-cell acute lymphoblastic leukemia
05/27/2010US20100130585 Methods and compositions for investigation and treatment of cancer using a g-protein coupled eicosanoid receptor
05/27/2010US20100130584 Novel compounds from antrodia camphorata
05/27/2010US20100130583 Prolinamide derivatives as modulators of voltage-gated sodium channels
05/27/2010US20100130582 Indolinone modulators of dopamine receptor
05/27/2010US20100130581 Compounds and methods for the treatment of pain
05/27/2010US20100130580 Formulations and Methods for Treating Dry Eye
05/27/2010US20100130579 Cancer therapy
05/27/2010US20100130577 Pyrazalone derivative formulations
05/27/2010US20100130576 Pharmaceutical composition
05/27/2010US20100130575 Compound with anesthetics activity, methods for its production and pharmaceutical compositions comprising the same
05/27/2010US20100130574 Neurodegenerative diseases and methods of modeling
05/27/2010US20100130573 Treatment and prevention of deleterious effects associated with alcohol consumption
05/27/2010US20100130572 Cytoskeletal active compounds, composition and use
05/27/2010US20100130571 Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof
05/27/2010US20100130569 Prophylactic or therapeutic agent for posterior ocular disease comprising non-ergot selective d2 receptor agonist as active ingredient
05/27/2010US20100130568 Topical compositions comprising telmesteine for treating dermatological disorders
05/27/2010US20100130567 Medical agent for prevention or treatment of alzheimer 's disease
05/27/2010US20100130566 Treatment of autism spectrum disorders with agents that activate the Locus Coeruleus - Noradrenergic system
05/27/2010US20100130565 Thioamide compounds, method of making and method of using thereof
05/27/2010US20100130564 Small molecule inhibitors of bcl6
05/27/2010US20100130563 Inhibitors of plasma kallikrein
05/27/2010US20100130562 Stabilized Nicotine Chewing Gum
05/27/2010US20100130559 Novel phenyl-isoxazol-3-ol derivative
05/27/2010US20100130558 Novel substituted octahydrocyclopenta[c]pyrrol-4-amines as calcium channel blockers
05/27/2010US20100130557 Substituted arylsulphonylglycines, the preparation thereof and the use thereof as pharmaceutical compositions
05/27/2010US20100130556 Ep2 receptor agonists
05/27/2010US20100130555 Compositions and methods for treating or preventing hypoxic or ischemic injury
05/27/2010US20100130554 Use of 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for the treatment of motor disorders related to parkinson's disease
05/27/2010US20100130553 Use of 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxido-4-pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide in the treatment of cranial traumas
05/27/2010US20100130552 Therapeutic Agents Useful for Treating Pain
05/27/2010US20100130551 Sufentanil Solid Dosage Forms Comprising Oxygen Scavengers and Methods of Using the Same
05/27/2010US20100130550 Ocular formulations of norketotifen
05/27/2010US20100130549 Psychotropic compounds, compositions and methods of use
05/27/2010US20100130548 Biphenyl derivatives as modulators of voltage gated ion channels
05/27/2010US20100130547 Solid forms of n-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-(trifluorormethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihyroquinoline-3-carboxamide
05/27/2010US20100130546 Quinolone compound and pharmaceutical composition
05/27/2010US20100130545 Bridged six-membered ring compounds
05/27/2010US20100130544 Use of parasympatholytic substances to enhance and accelerate stem cell differentiation, related methods and compositions
05/27/2010US20100130543 Pyrazole carboxamide inhibitors of factor xa
05/27/2010US20100130542 Composition Comprising a Combination of Omeprazole and Lansoprazole, and a Buffering Agent, and Methods of Using Same
05/27/2010US20100130541 Processes for the preparation of clopidogrel
05/27/2010US20100130540 Azaquinolinone derivatives and uses thereof
05/27/2010US20100130539 Imidazopyridine inhibitors of iap
05/27/2010US20100130538 Bicyclic compound and pharmaceutical use thereof
05/27/2010US20100130537 Cinnamide compounds for dementia
05/27/2010US20100130536 Methods for controlling formation of imiquimod impurities for two months, four months, and six months
05/27/2010US20100130535 Methods for stabilizing imiquimod for two months, four months, and six months
05/27/2010US20100130534 Methods for reducing imiquimod impurities for two months, four months, and six months
05/27/2010US20100130533 Pharmaceutical creams with refined oleic acid
05/27/2010US20100130532 Reduction of imiquimod impurities in pharmaceutical creams
05/27/2010US20100130531 Pharmaceutical creams with reduced imiquimod impurities
05/27/2010US20100130530 Reduction of imiquimod impurities using refined oleic acid
05/27/2010US20100130529 Method of stabilizing imiquimod
05/27/2010US20100130528 Adamantane modulators of nmda receptor and/or 5ht3 receptor
05/27/2010US20100130527 Individualized cancer treatment
05/27/2010US20100130526 Methods for Disease Therapy
05/27/2010US20100130525 Aqueous solution preparation containing camptothecin compounds
05/27/2010US20100130524 Therapeutic or prophylactic agent for dyskinesia
05/27/2010US20100130523 Mono-hydrochloric salts of an inhibitor of histone deacetylase
05/27/2010US20100130522 Compounds for inflammation and immune-related uses
05/27/2010US20100130521 Method of treatment using fused aromatic compounds having anti-diabetic activity
05/27/2010US20100130520 Combination therapy
05/27/2010US20100130519 Combination therapy comprising azd2171 and azd6244 or mek-inhibitor ii
05/27/2010US20100130518 Mapk/erk kinase inhibitors
05/27/2010US20100130517 New 4,8-diphenyl-polyazanaphthalene derivatives
05/27/2010US20100130516 Purinyl derivatives and their use as potassium channel modulators
05/27/2010US20100130515 Polymorphs and solvates of a pharmaceutical and method of making
05/27/2010US20100130514 Fused heterocyclic derivative, pharmaceutical composition comprising the derivative, and use of the composition for medical purposes
05/27/2010US20100130513 Benzimidazoles and analogs thereof as antivirals
05/27/2010US20100130512 Fused-ring heterocycle opioids
05/27/2010US20100130511 Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders
05/27/2010US20100130510 Compounds for inflammation and immune-related uses
05/27/2010US20100130509 Novel antibiotics
05/27/2010US20100130508 Pharmaceutical composition comprising 2,3-dihydro-6-nitroimidazo [2,1-b] oxazole derivatives
05/27/2010US20100130507 Prostaglandin derivatives
05/27/2010US20100130506 Organic Compounds
05/27/2010US20100130505 Compositions and methods for inhibiting g protein signaling
05/27/2010US20100130504 Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
05/27/2010US20100130503 New fluorene derivatives, compositions containing the same and use thereof as inhibitors of the protein chaperone hsp 90
05/27/2010US20100130502 Compounds, Formulations, and Methods for Treating or Preventing Inflammatory Skin Disorders
05/27/2010US20100130501 Novel 3-amino-pyrrolo[3,4-c]pyrazole-5(1h, 4h, 6h) carbaldehyde derivatives
05/27/2010US20100130500 Methods and compositions for the treatment of pulmonary hypertension of the newborn
05/27/2010US20100130499 Bicycloheteroaryl compounds and their use as trpv1 ligands
05/27/2010US20100130498 Agonists of bitter taste receptors and uses thereof
05/27/2010US20100130497 Therapeutic Compounds
05/27/2010US20100130496 Pyrimidine derivatives as inhibitors of phosphatidylinositol-3-kinase
05/27/2010US20100130495 Compounds 563
1 ... 2250 2251 2252 2253 2254 2255 2256 2257 2258 2259 2260 2261 2262 2263 2264 2265 2266 2267 2268 2269 2270 ... 7860